
Susanna Proudman
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.
Dr Susanna Proudman graduated from Adelaide University in 1987 and trained in rheumatology at the Royal Adelaide Hospital where she is now Rheumatology Unit Director. As an ARA Michael Mason Fellow, she trained with Professor Paul Emery in Leeds, establishing one of the first Early Arthritis Clinics in the world.
Recent research interests include “best practice” management of early rheumatoid arthritis with an emphasis on “treat-to-target” therapy, the role of omega-3 fatty acids and periodontal disease and standardized management of systemic sclerosis and pulmonary arterial hypertension. In establishing a “Centre of Excellence” for the treatment of PAH in SSc and as Chair of the Australian Scleroderma Interest Group, she established the Australian Scleroderma Cohort Study in 2007 with collaborations such as the International Systemic Sclerosis Inception Cohort (INSYNC) and the Scleroderma Clinical Trials Consortium Damage Index working group. She is Medical Director of Arthritis Australia and Chair of the Actelion Clinical Excellence Program.
- My Research
- Career
- Publications
- Grants and Funding
- Teaching
- Supervision
- Professional Activities
- Contact
My Research
Susanna Proudman graduated from Adelaide University in 1987 and trained in rheumatology at the Royal Adelaide Hospital where she is now Rheumatology Unit Director. As an ARA Michael Mason Fellow, she trained with Professor Paul Emery in Leeds, establishing one of the first Early Arthritis Clinics in the world.
Recent research interests include “best practice” management of early rheumatoid arthritis with an emphasis on “treat-to-target” therapy, the role of omega-3 fatty acids and periodontal disease and standardized management of systemic sclerosis and pulmonary arterial hypertension. In establishing a “Centre of Excellence” for the treatment of PAH in SSc and as Chair of the Australian Scleroderma Interest Group, she established the Australian Scleroderma Cohort Study in 2007 with collaborations such as the International Systemic Sclerosis Inception Cohort (INSYNC) and the Scleroderma Clinical Trials Consortium Damage Index working group. She is Medical Director of Arthritis Australia and Chair of the Actelion Clinical Excellence Program.
-
Expand
-
Appointments
Date Position Institution name 2016 Head of Unit Royal Adelaide Hospital, Adelaide 2012 - 2014 Clinical lead Central Adelaide Local Health Network 2011 Clinical Associate Professor University of Adelaide 2011 - 2015 Research Scientist - Grade 5 Royal Adelaide Hospital, Adelaide 1998 Senior Staff Specialist, Rheumatology Royal Adelaide Hospital -
Awards and Achievements
Date Type Title Institution Name Country Amount 2014 Award Taverner Award for best presentation — — — 2013 Award State ARA award for best clinical presentation — — — 2012 Award Award for Best Clinical Paper — — — -
Education
Date Institution name Country Title 1994 Royal Australasian College of Physicians, Sydney Australia Fellow 1990 Royal Australasian College of Physicians, Sydney Australia Part I; Fellowship Examination — University of Adelaide Australia MBBS (Hons) -
Certifications
Date Title Institution name Country 2014 Fellow Royal Australasian College of Physicians — -
Research Interests
-
Expand
-
Journals
Year Citation 2020 Ross, L., Stevens, W., Wilson, M., Strickland, G., Walker, J., Sahhar, J., . . . Nikpour, M. (2020). Can patient-reported symptoms be used to measure disease activity in systemic sclerosis?. Arthritis Care and Research, 72(10), 1459-1465.
Scopus1 WoS2 Europe PMC12020 Morrisroe, K., Hansen, D., Huq, M., Stevens, W., Sahhar, J., Ngian, G. S., . . . Nikpour, M. (2020). Incidence, Risk Factors, and Outcomes of Cancer in Systemic Sclerosis. Arthritis Care and Research, 72(11), 1625-1635.
Scopus2 Europe PMC12020 Abbot, S., McWilliams, L., Spargo, L., de Costa, C., Ur-Rehman, Z., Proudman, S., & Bossingham, D. (2020). Scleroderma in Cairns: an epidemiological study. Internal Medicine Journal, 50(4), 445-452.
2020 Quinlivan, A., Ross, L., & Proudman, S. (2020). Systemic sclerosis: Advances towards stratified medicine. Best Practice and Research: Clinical Rheumatology, 34(1), 22 pages.
Scopus1 WoS12020 Khadra, Y., Walker, J. G., Hakendorf, P., Proudman, S., Rischmueller, M., Hill, C. L., . . . Roberts-Thomson, P. J. (2020). Scleroderma Renal Crisis: Observations from the South Australian Scleroderma Register.. Internal medicine journal.
2020 Ruediger, C., Nguyen, L., Black, R., Proudman, S., & Hill, C. (2020). Efficacy of Methotrexate in Polymyalgia Rheumatica in routine rheumatology clinical care.. Internal medicine journal, 50(9), 1067-1072.
2020 Morrisroe, K., Stevens, W., Sahhar, J., Ngian, G. S., Ferdowsi, N., Hansen, D., . . . Nikpour, M. (2020). The clinical and economic burden of systemic sclerosis related interstitial lung disease. Rheumatology (Oxford, England), 59(8), 1878-1888.
Scopus1 WoS12020 Proudman, S. (2020). Consensus statements for managing systemic sclerosis-associated interstitial lung disease. The Lancet Rheumatology, 2(2), e64-e65.
2020 Anderson, J., Lavender, M., Lau, E., Celermajer, D., Collins, N., Dwyer, N., . . . Strange, G. (2020). Pharmacological Treatment of Pulmonary Arterial Hypertension in Australia: Current Trends and Challenges. Heart Lung and Circulation, 29(10), 1459-1468.
2020 Wiese, M. D., Hopkins, A. M., King, C., Wechalekar, M. D., Lee, A., Spargo, L., . . . Proudman, S. M. (2020). Precision Medicine with Leflunomide: Consideration of DHODH Haplotype and Plasma Teriflunomide Concentration can Substantially Modify Outcomes in Patients with Rheumatoid Arthritis.. Arthritis care & research.
2020 Day, J., Otto, S., Cash, K., Eldi, P., Hissaria, P., Proudman, S., . . . Hayball, J. D. (2020). Aberrant expression of high mobility group box protein 1 in the idiopathic inflammatory myopathies. Frontiers in Cell and Developmental Biology, 8, 11 pages.
2020 Thombs, B. D., Kwakkenbos, L., Carrier, M. -E., Bourgeault, A., Tao, L., Harb, S., . . . Ostbo, N. (2020). Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. JOURNAL OF PSYCHOSOMATIC RESEARCH, 135, 11 pages.
WoS12020 Foers, A. D., Garnham, A. L., Smyth, G. K., Proudman, S. M., Cheng, L., Hill, A. F., . . . Wicks, I. P. (2020). Circulating Small Noncoding RNA Biomarkers of Response to Triple Disease-modifying Antirheumatic Drug Therapy in White Women With Early Rheumatoid Arthritis.. The Journal of rheumatology, jrheum.191012.
2020 Murray-Brown, W., Wilsdon, T. D., Weedon, H., Proudman, S., Sukumaran, S., Klebe, S., . . . Wechalekar, M. D. (2020). Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy. Journal for ImmunoTherapy of Cancer, 8(1), 6 pages.
Scopus1 WoS12020 Reid, A. B., Wiese, M., McWilliams, L., Metcalf, R., Hall, C., Lee, A., . . . Proudman, S. M. (2020). Repeat serological testing for anti-citrullinated peptide antibody after commencement of therapy is not helpful in patients with seronegative rheumatoid arthritis. Internal Medicine Journal, 50(7), 818-822.
2020 Ross, L., Stevens, W., Wilson, M., Huq, M., Strickland, G., Walker, J., . . . Nikpour, M. (2020). Performance of the 2017 EUSTAR activity index in an scleroderma cohort. Clinical Rheumatology, OnlinePubl., [1]-[5].
2020 Valenzuela, A., Baron, M., Rodriguez-Reyna, T. S., Proudman, S., Khanna, D., Young, A., . . . Chung, L. (2020). Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis. Seminars in Arthritis and Rheumatism, 50(5), 891-896.
2020 Patel, S., Morrisroe, K., Proudman, S., Hansen, D., Sahhar, J., Sim, M. R., . . . Australian Scleroderma Interest Group. (2020). Occupational silica exposure in an Australian systemic sclerosis cohort.. Rheumatology (Oxford, England).
2020 Abuhelwa, A. Y., Hopkins, A. M., Sorich, M. J., Proudman, S., Foster, D. J. R., & Wiese, M. D. (2020). Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. Scientific Reports, 10(1), 18634.
2019 Morrisroe, K., Stevens, W., Sahhar, J., Ngian, G. -S., Ferdowsi, N., Hansen, D., . . . Nikpour, M. (2019). The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia. BMC Pulmonary Medicine, 19(1), 226-1-226-11.
2019 Morrisroe, K., Stevens, W., Sahhar, J., Ngian, G. -S., Ferdowsi, N., Hill, C. L., . . . Nikpour, M. (2019). Digital ulcers in systemic sclerosis: their epidemiology, clinical characteristics, and associated clinical and economic burden. Arthritis Research and Therapy, 21(1), 299-1-299-12.
Scopus2 WoS3 Europe PMC12019 López-Isac, E., Acosta-Herrera, M., Kerick, M., Assassi, S., Satpathy, A. T., Granja, J., . . . Chang, H. Y. (2019). GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. Nature Communications, 10(1), 14 pages.
Scopus9 WoS10 Europe PMC32019 Quinlivan, A., Proudman, S., Sahhar, J., Stevens, W., Nikpour, M., Major, G., . . . Youseff, P. (2019). Cost savings with a novel algorithm for early detection of systemic sclerosis-related pulmonary arterial hypertension: alternative scenario analyses. Internal Medicine Journal, 49(6), 781-785.
Scopus3 WoS22019 Boulos, D., Proudman, S., Metcalf, R., McWilliams, L., Hall, C., & Wicks, I. (2019). The neutrophil-lymphocyte ratio in early rheumatoid arthritis and its ability to predict subsequent failure of triple therapy. Seminars in Arthritis and Rheumatism, 49(3), 373-376.
Scopus2 WoS2 Europe PMC12019 Harel, D., Mills, S. D., Kwakkenbos, L., Carrier, M. -E., Nielsen, K., Portales, A., . . . Lambert, M. (2019). Shortening patient-reported outcome measures through optimal test assembly: application to the Social Appearance Anxiety Scale in the Scleroderma Patient-centered Intervention Network Cohort. BMJ OPEN, 9(2), 10 pages.
WoS32019 Metwally, M., Thabet, K., Bayoumi, A., Nikpour, M., Stevens, W., Sahhar, J., . . . Eslam, M. (2019). IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis. Scientific Reports, 9(1), 14834.
Scopus4 WoS32019 Khoo, T., Stokes, M. B., Teo, K., Proudman, S., Basnayake, S., Sanders, P., & Limaye, V. (2019). Cardiac involvement in idiopathic inflammatory myopathies detected by cardiac magnetic resonance imaging. Clinical Rheumatology, 38(12), 3471-3476.
Scopus3 WoS3 Europe PMC12019 Maundrell, A., Proudman, S., & Limaye, V. (2019). Prevalence of other connective tissue diseases in idiopathic inflammatory myopathies. Rheumatology International, 39(10), 1777-1781.
Scopus3 WoS32019 Butler, E. A., Baron, M., Fogo, A. B., Frech, T., Ghossein, C., Hachulla, E., . . . Walker, U. A. (2019). Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. Arthritis and Rheumatology, 71(6), 964-971.
Scopus8 WoS6 Europe PMC22019 Khoo, T., Proudman, S., & Limaye, V. (2019). Silicone breast implants and depression, fibromyalgia and chronic fatigue syndrome in a rheumatology clinic population. Clinical Rheumatology, 38(5), 1271-1276.
Scopus3 WoS3 Europe PMC22019 Wabe, N., Lee, A., Wechalekar, M., McWilliams, L., Proudman, S., & Wiese, M. (2019). Factors associated with medication adherence in a longitudinal study of rheumatoid arthritis patients. International Journal of Clinical Practice, 73(7), 9 pages.
Scopus2 WoS2 Europe PMC12019 Ross, L., Prior, D., Proudman, S., Vacca, A., Baron, M., & Nikpour, M. (2019). Defining primary systemic sclerosis heart involvement: a scoping literature review. Seminars in Arthritis and Rheumatism, 48(5), 874-887.
Scopus7 WoS72019 Moxey, J., Huq, M., Proudman, S., Sahhar, J., Ngian, G. S., Walker, J., . . . Nikpour, M. (2019). Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis. Arthritis Research and Therapy, 21(1), 57-1-57-12.
Scopus6 WoS52019 Richard, N., Hudson, M., Wang, M., Gyger, G., Proudman, S., Stevens, W., . . . Baron, M. (2019). Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. Rheumatology, 58(4), 636-644.
Scopus13 WoS14 Europe PMC22019 McMahan, Z. H., Frech, T., Berrocal, V., Lim, D., Bruni, C., Matucci-Cerinic, M., . . . Khanna, D. (2019). Longitudinal assessment of patient-reported outcome measures in systemic sclerosis patients with gastroesophageal reflux disease - Scleroderma clinical trials consortium. Journal of Rheumatology, 46(1), 78-84.
Scopus4 WoS2 Europe PMC12019 Ferdowsi, N., Huq, M., Stevens, W., Hudson, M., Wang, M., Tay, T., . . . Nikpour, M. (2019). Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): A novel instrument to quantify organ damage in systemic sclerosis. Annals of the Rheumatic Diseases, 78(6), 807-816.
Scopus9 WoS7 Europe PMC12018 Abbot, S., Bossingham, D., Proudman, S., de Costa, C., & Ho-Huynh, A. (2018). Risk factors for the development of systemic sclerosis: A systematic review of the literature. Rheumatology Advances in Practice, 2(2), 1-12.
Scopus42018 Massolino, R. I., Hissaria, P., Lee, A., & Proudman, S. M. (2018). Tocilizumab-induced drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient with rheumatoid arthritis. Rheumatology Advances in Practice, 2(2), 1-2.
Scopus12018 Wilsdon, T., & Proudman, S. (2018). Early arthritis: A guide to assessment. Medicine Today, 19(11), 12-18. 2018 Morrisroe, K., Hudson, M., Baron, M., De Vries-Bouwstra, J., Carreira, P., Wuttge, D., . . . Nikpour, M. (2018). Determinants of health-related quality of life in a multinational systemic sclerosis inception cohort. Clinical and Experimental Rheumatology, 36(Suppl. 113), S53-S60.
Scopus7 WoS6 Europe PMC12018 Ross, L., Stevens, W., Rabusa, C., Wilson, M., Ferdowsi, N., Walker, J., . . . Nikpour, M. (2018). The role of inflammatory markers in assessment of disease activity in systemic sclerosis. Clinical and Experimental Rheumatology, 36(4), S126-S134.
Scopus11 Europe PMC22018 Thakkar, V., Patterson, K., Stevens, W., Wilson, M., Roddy, J., Sahhar, J., . . . Nikpour, M. (2018). Increased serum levels of adhesion molecules ICAM-1 and VCAM-1 in systemic sclerosis are not specific for pulmonary manifestations. Clinical Rheumatology, 37(6), 1563-1571.
Scopus4 WoS4 Europe PMC12018 Cole, S., Walsh, A., Yin, X., Wechalekar, M., Smith, M., Proudman, S., . . . Guo, Y. (2018). Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus. Arthritis Research and Therapy, 20(1), 14 pages.
Scopus20 WoS15 Europe PMC82018 Strange, G., Lau, E., Giannoulatou, E., Corrigan, C., Kotlyar, E., Kermeen, F., . . . Keogh, A. (2018). Survival of Idiopathic Pulmonary Arterial Hypertension Patients in the Modern Era in Australia and New Zealand. Heart Lung and Circulation, 27(11), 1368-1375.
Scopus9 WoS9 Europe PMC22018 Herrick, A., Peytrignet, S., Lunt, M., Pan, X., Hesselstrand, R., Mouthon, L., . . . Denton, C. (2018). Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Annals of the Rheumatic Diseases, 77(4), 563-570.
Scopus17 WoS18 Europe PMC62018 Guo, Y., Walsh, A., Canavan, M., Wechalekar, M., Cole, S., Yin, X., . . . Nagpal, S. (2018). Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. PLoS ONE, 13(2), 17 pages.
Scopus34 WoS34 Europe PMC142018 Morrisroe, K., Sudararajan, V., Stevens, W., Sahhar, J., Zochling, J., Roddy, J., . . . Nikpour, M. (2018). Work productivity in systemic sclerosis, its economic burden and association with health-related quality of life.. Rheumatology (Oxford, England), 57(1), 73-83.
Scopus5 WoS5 Europe PMC12018 Peytrignet, S., Denton, C., Lunt, M., Hesselstrand, R., Mouthon, L., Silman, A., . . . Herrick, A. (2018). Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study.. Rheumatology (Oxford, England), 57(2), 370-381.
Scopus19 WoS14 Europe PMC42017 Morrisroe, K., Stevens, W., Sahhar, J., Ngian, G., Rabusa, C., Ferdowsi, N., . . . Nikpour, M. (2017). Quantifying the direct public health care cost of systemic sclerosis. Medicine, 96(48), e8503-1-e8503-11.
Scopus6 WoS6 Europe PMC12017 Hopkins, A., Vitry, A., O'Doherty, C., Proudman, S., & Wiese, M. (2017). Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide. International Journal of Rheumatic Diseases, 20(11), 1795-1797.
Scopus1 WoS12017 Morrisroe, K., Stevens, W., Proudman, S., & Nikpour, M. (2017). A systematic review of the epidemiology, disease characteristics and management of systemic sclerosis in Australian adults. International Journal of Rheumatic Diseases, 20(11), 1728-1750.
Scopus6 WoS52017 Rasch, L., Boers, M., Hill, C., Voshaar, M., Hoogland, W., De Wit, M., . . . Van Tuyl, L. (2017). Validating rheumatoid arthritis remission using the patients' perspective: Results from a special interest group at OMERACT 2016. Journal of Rheumatology, 44(12), 1889-1893.
Scopus4 WoS4 Europe PMC22017 Walsh, A., Wechalekar, M., Guo, Y., Yin, X., Weedon, H., Proudman, S., . . . Nagpal, S. (2017). Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast/plasma cell differentiation pathways. PLoS ONE, 12(9), e0183928-1-e0183928-16.
Scopus12 WoS14 Europe PMC92017 Wabe, N., Wojciechowski, J., Wechalekar, M., Cleland, L., McWilliams, L., Lee, A., . . . Wiese, M. (2017). Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy. International Journal of Rheumatic Diseases, 20(10), 1447-1456.
Scopus2 WoS22017 Herrick, A., Pan, X., Peytrignet, S., Lunt, M., Hesselstrand, R., Mouthon, L., . . . Denton, C. (2017). Treatment outcome in early diffuse cutaneous systemic sclerosis: The European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases, 76(7), 1207-1218.
Scopus48 WoS48 Europe PMC142017 Wabe, N., Lee, A., Wechalekar, M., McWilliams, L., Proudman, S., & Wiese, M. (2017). Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users. Rheumatology International, 37(6), 897-904.
Scopus7 WoS8 Europe PMC62017 Wechalekar, M., Quinn, S., Lester, S., Metcalf, R., Shanahan, E., Walker, J., . . . Proudman, S. (2017). A treat-to-target strategy preserves work capacity in a rheumatoid arthritis inception cohort treated with combination conventional DMARD therapy. Journal of Clinical Rheumatology, 23(3), 131-137.
Scopus3 WoS3 Europe PMC12017 Day, J., Limaye, V., Proudman, S., Hayball, J., & Hissaria, P. (2017). The utility of monitoring peripheral blood lymphocyte subsets by flow cytometric analysis in patients with rheumatological diseases treated with rituximab. Autoimmunity Reviews, 16(5), 542-547.
Scopus3 WoS32017 Morrisroe, K., Stevens, W., Sahhar, J., Rabusa, C., Nikpour, M., Proudman, S., . . . Zochling, J. (2017). Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. Arthritis Research and Therapy, 19(1), 42-1-42-10.
Scopus33 WoS31 Europe PMC132017 Nikpour, M., Proudman, S., Morrisroe, K., Sahhar, J., & Stevens, W. (2017). The Australian scleroderma interest group and database: 10 years of screening to save lives. Medical Journal of Australia, 206(5), 229-229.e1.
Scopus1 WoS12017 Boulos, D., Ngian, G., Rajadurai, A., Elford, K., Stevens, W., Proudman, S., . . . Sahhar, J. (2017). Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease. International Journal of Rheumatic Diseases, 20(4), 481-488.
Scopus7 WoS7 Europe PMC12017 Otero, C., Assassi, S., Hudson, M., Mayes, M., Estrada-Y-Martin, R., Pedroza, C., . . . Fritzler, M. (2017). Antifibrillarin antibodies are associated with native north American ethnicity and poorer survival in systemic sclerosis. Journal of Rheumatology, 44(6), 799-805.
Scopus8 WoS72017 Tay, T., Ferdowsi, N., Baron, M., Stevens, W., Hudson, M., Proudman, S., . . . Damage Index Working Group of the Scleroderma Clinical Trials Consortium. (2017). Measures of disease status in systemic sclerosis: a systematic review. Seminars in Arthritis and Rheumatism, 46(4), 473-487.
Scopus10 WoS8 Europe PMC42017 Hoa, S., Stern, E. P., Denton, C. P., Hudson, M., Baron, M., Frech, T., . . . Varga, J. (2017). Towards developing criteria for scleroderma renal crisis: A scoping review. Autoimmunity Reviews, 16(4), 407-415.
Scopus18 Europe PMC102017 Ramos-Remus, C., Ramirez-Gomez, A., Brambila-Barba, V., Barajas-Ochoa, A., Castillo-Ortiz, J. D., Adebajo, A. O., . . . Mæland, E. (2017). Latitude gradient influences the age of onset of rheumatoid arthritis: a worldwide survey. Clinical Rheumatology, 36(3), 485-497.
Scopus12 WoS11 Europe PMC32017 Guo, Y., Walsh, A., Fearon, U., Smith, M., Wechalekar, M., Yin, X., . . . Nagpal, S. (2017). CD40L-dependent pathway is active at various stages of rheumatoid arthritis disease progression. Journal of Immunology, 198(11), 4490-4501.
Scopus22 WoS21 Europe PMC142017 Morrisroe, K., Stevens, W., Huq, M., Sahhar, J., Ngian, G., Zochling, J., . . . ustralian Scleroderma Interest Group (ASIG). (2017). Validity of the Workers Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) in patients with systemic sclerosis. Clinical and Experimental Rheumatology, 35(4 Suppl. 106), S130-S137.
Scopus5 WoS5 Europe PMC12017 Morrisroe, K., Stevens, W., Huq, M., Prior, D., Sahhar, J., Ngian, G., . . . Walker, J. (2017). Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. Arthritis Research and Therapy, 19(1), 122.
Scopus20 WoS20 Europe PMC122017 Proudman, S. M., Huq, M., Stevens, W., Wilson, M. E., Sahhar, J., Baron, M., . . . Scheja, A. (2017). What have multicentre registries across the world taught us about the disease features of systemic sclerosis?. Journal of Scleroderma and Related Disorders, 2(3), 169-182.
Scopus82017 Morrisroe, K., Stevens, W., Huq, M., Sahhar, J., Ngian, G. S., Zochling, J., . . . Walker, J. (2017). Validity of the PROMIS-29 in a large Australian cohort of patients with systemic sclerosis. Journal of Scleroderma and Related Disorders, 2(3), 188-195.
Scopus22017 Tay, T., Huq, M., Ferdowsi, N., Stevens, W., Sahhar, J., Ngian, G. S., . . . Nikpour, M. (2017). Early accrual of organ damage in systemic sclerosis: Rationale for development of a disease damage index. Journal of Scleroderma and Related Disorders, 2(2), 127-134.
Scopus32017 Day, J., Otto, S., Proudman, S., Hayball, J., & Limaye, V. (2017). Dysregulated innate immune function in the aetiopathogenesis of idiopathic inflammatory myopathies. Autoimmunity Reviews, 16(1), 87-95.
Scopus10 WoS10 Europe PMC62017 Hopkins, A., Moghaddami, M., Foster, D., Proudman, S., Upton, R., & Wiese, M. (2017). Intracellular CD3⁺ T-lymphocyte teriflunomide concentration is poorly correlated with and has greater variability than unbound plasma teriflunomide concentration. Drug Metabolism Disposition, 45(1), 8-16.
Scopus5 WoS42017 Hopkins, A., Wiese, M., O Doherty, C., & Proudman, S. (2017). Putting recommendations into practice: Australian rheumatologists’ opinions on leflunomide use in rheumatoid arthritis. Clinical Rheumatology, 36(4), 791-798.
Scopus2 WoS2 Europe PMC12017 Hao, Y., Hudson, M., Baron, M., Carreira, P., Stevens, W., Rabusa, C., . . . Nikpour, M. (2017). Early mortality in a multinational systemic sclerosis inception cohort. Arthritis and Rheumatology, 69(5), 1067-1077.
Scopus65 WoS56 Europe PMC272017 Foreman, C., Russo, P., Davies, N., Hissaria, P., Proudman, S., Hughes, T., & Limaye, V. (2017). Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients. Internal Medicine Journal, 47(1), 112-115.
Scopus4 WoS4 Europe PMC22017 Wabe, N., Sorich, M., Wechalekar, M., Cleland, L., Mcwilliams, L., Lee, A., . . . Wiese, M. (2017). Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis. International Journal of Rheumatic Diseases, 20(5), 576-583.
Scopus4 WoS5 Europe PMC42016 Hopkins, A., Wiese, M., Proudman, S., O'Doherty, C., Upton, R., & Foster, D. (2016). Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis. British Journal of Clinical Pharmacology, 81(1), 113-123.
Scopus13 WoS11 Europe PMC52016 Hill, C., March, L., Aitken, D., Lester, S., Battersby, R., Hynes, K., . . . Jones, G. (2016). Fish oil in knee osteoarthritis: a randomised clinical trial of low dose versus high dose. Annals of the Rheumatic Diseases, 75(1), 23-29.
Scopus55 WoS43 Europe PMC262016 Calderone, A., Stevens, W., Prior, D., Nandurkar, H., Gabbay, E., Proudman, S., . . . Nikpour, M. (2016). Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol. BMJ Open, 6(12), e011028-1-e011028-12.
Scopus8 WoS8 Europe PMC42016 Tieu, J., & Proudman, S. (2016). Systemic sclerosis a step-by-step guide to a difficult diagnosis. Medicine Today, 17(9), 47-54. 2016 Esposito, J., Brown, Z., Stevens, W., Sahhar, J., Rabusa, C., Zochling, J., . . . Nikpour, M. (2016). The association of low complement with disease activity in systemic sclerosis: a prospective cohort study. Arthritis Research and Therapy, 18(1), 246-1-246-12.
Scopus6 WoS3 Europe PMC42016 Morrisroe, K., Huq, M., Stevens, W., Rabusa, C., Proudman, S., & Nikpour, M. (2016). Determinants of unemployment amongst Australian systemic sclerosis patients: Results from a multicentre cohort study. Clinical and Experimental Rheumatology, 34(5), 79-84.
Scopus10 WoS11 Europe PMC42016 Morrisroe, K., Huq, M., Stevens, W., Rabusa, C., Proudman, S., Nikpour, M., & The Australian Scleroderma Interest Group (ASIG). (2016). Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study. BMC Pulmonary Medicine, 16(1), 134-1-134-8.
WoS18 Europe PMC72016 Morrisroe, K., Huq, M., Stevens, W., Rabusa, C., Proudman, S., & Nikpour, M. (2016). Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: Results from a large multicenter cohort study. BMC Pulmonary Medicine, 16(1), 33.
Scopus182016 Valenzuela, A., Baron, M., Herrick, A., Proudman, S., Stevens, W., Rodriguez-Reyna, T., . . . Chung, L. (2016). Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study. Seminars in Arthritis and Rheumatism, 46(3), 344-349.
Scopus32 WoS28 Europe PMC62016 Wabe, N., Sorich, M., Wechalekar, M., Cleland, L., McWilliams, L., Lee, A., . . . Wiese, M. (2016). Effect of adherence to protocolized targeted intensifications of disease-modifying antirheumatic drugs on treatment outcomes in rheumatoid arthritis: results from an Australian early arthritis cohort. The Journal of Rheumatology, 43(9), 1643-1649.
Scopus7 WoS7 Europe PMC32016 Proudman, S., Nikpour, M., & Hudson, M. (2016). Improving care of autoimmune connective tissue diseases: Lessons from longitudinal cohorts. Best Practice and Research: Clinical Rheumatology, 30(1), 1-2.
2016 Hoa, S., Hudson, M., Troyanov, Y., Proudman, S., Walker, J., Stevens, W., . . . Fritzler, M. (2016). Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: Clinical associations. Medicine (United States), 95(35), 12 pages.
Scopus20 WoS18 Europe PMC62016 Wojciechowski, J., Wiese, M., Proudman, S., Foster, D., & Upton, R. (2016). A model-based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity. British Journal of Clinical Pharmacology, 81(6), 1046-1057.
2016 Hopkins, A., Proudman, S., Vitry, A., Sorich, M., Cleland, L., & Wiese, M. (2016). Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia. Medical Journal of Australia, 204(2), 64-68.e1.
Scopus8 WoS5 Europe PMC22016 Khanna, D., Berrocal, V., Giannini, E., Seibold, J., Merkel, P., Mayes, M., . . . Furst, D. (2016). The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology, 68(2), 299-311.
Scopus51 WoS52 Europe PMC222016 Khanna, D., Berrocal, V., Giannini, E., Seibold, J., Merkel, P., Mayes, M., . . . Furst, D. (2016). The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Care and Research, 68(2), 167-178.
Scopus7 WoS4 Europe PMC12016 Wechalekar, M., Lester, S., Hill, C., Lee, A., Rischmueller, M., Smith, M., . . . Proudman, S. (2016). Active foot synovitis in patients with rheumatoid arthritis: unstable remission status, radiographic progression, and worse functional outcomes in patients with foot synovitis in apparent remission. Arthritis Care and Research, 68(11), 1616-1623.
Scopus19 WoS18 Europe PMC102016 Wabe, N., Sorich, M., Wechalekar, M., Cleland, L., McWilliams, L., Lee, A., . . . Wiese, M. (2016). Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?. International Journal of Clinical Practice, 70(4), 340-350.
Scopus2 WoS2 Europe PMC12016 Owen, C., Ngian, G., Elford, K., Moore, O., Stevens, W., Nikpour, M., . . . Sahhar, J. (2016). Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort study. Clinical and Experimental Rheumatology, 34(5 (Suppl.100)), 170-176.
Scopus27 WoS23 Europe PMC82016 Nenke, M., Lewis, J., Rankin, W., McWilliams, L., Metcalf, R., Proudman, S., & Torpy, D. (2016). Reduced corticosteroid-binding globulin cleavage in active rheumatoid arthritis. Clinical Endocrinology, 85(3), 369-377.
Scopus8 WoS5 Europe PMC32016 Hynes, K., Bright, R., Proudman, S., Haynes, D., Gronthos, S., & Bartold, M. (2016). Immunomodulatory properties of mesenchymal stem cell in experimental arthritis in rat and mouse models: a systematic review. Seminars in Arthritis and Rheumatism, 46(1), 1-19.
Scopus15 WoS14 Europe PMC112016 Nikpour, M., Prior, D., Proudman, S., & Stevens, W. (2016). Author reply. Internal Medicine Journal, 46(6), 751-752.
2016 Thakkar, V., Stevens, W., Prior, D., Rabusa, C., Sahhar, J., G Walker, J., . . . Nikpour, M. (2016). The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study. Clinical and Experimental Rheumatology, 34(5 (Suppl.100)), 129-136.
Scopus8 WoS8 Europe PMC32016 Khanna, D., Denton, C., Merkel, P., Krieg, T., Le Brun, F., Marr, A., . . . Balbir-Gurman, A. (2016). Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: Dual-1 and Dual-2 randomized clinical trials. JAMA - Journal of the American Medical Association, 315(18), 1975-1988.
Scopus55 Europe PMC292016 Tieu, J., Lester, S., Whittle, S., Peh, C. A., Goldblatt, F., Proudman, S., . . . Hill, C. (2016). RITUXIMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS: A REVIEW OF USE IN SOUTH AUSTRALIA. INTERNAL MEDICINE JOURNAL, 46, 35. 2016 Leclair, V., Hudson, M., Proudman, S. M., Stevens, W. M., Fritzler, M. J., Wang, M., . . . Youssef, P. (2016). Subsets in systemic sclerosis: One size does not fit all. Journal of Scleroderma and Related Disorders, 1(3), 298-306.
Scopus42016 Hopkins, A. M., Proudman, S. M., Vitry, A. I., Sorich, M. J., Cleland, L. G., & Wiese, M. D. (2016). Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia. MEDICAL JOURNAL OF AUSTRALIA, 204(2), 64-+.
2015 Wechalekar, M. D., Lester, S., Rischmueller, M., Hill, C., & Proudman, S. (2015). Foot Synovitis in Patients with Rheumatoid Arthritis in Apparent Remission Is Associated with Unstable Remission Status, Radiographic Progression and Worse Long-Term Functional Outcomes. ARTHRITIS & RHEUMATOLOGY, 67, 2 pages. 2015 Wabe, N., Sorich, M., Wechalekar, M., Cleland, L., McWilliams, L., Lee, A., . . . Wiese, M. D. (2015). Effects of Drug Induced Toxicity on Patient Reported Outcomes in Early Rheumatoid Arthritis Treated-to-Target Using Conventional Triple DMARD Therapy. ARTHRITIS & RHEUMATOLOGY, 67, 2 pages. 2015 Johnson, S. R., Elarabi, M., Proudman, S., Frech, T. M., Sahhar, J., Stevens, W., . . . Hudson, M. (2015). Exposure to ACE Inhibitors Prior to Onset of Scleroderma Renal Crisis Is Not Associated with Increased Risk of Mortality in a Large Retrospective Cohort Study. ARTHRITIS & RHEUMATOLOGY, 67, 2 pages. 2015 Valenzuela, A., Baron, M., Herrick, A. L., Proudman, S., Stevens, W., Sofia Rodriguez-Reyna, T., . . . Chung, L. (2015). Calcinosis Is Associated with Digital Ulcers and Osteoporosis in Patients with Systemic Sclerosis. ARTHRITIS & RHEUMATOLOGY, 67, 2 pages. 2015 Hudson, M., Baron, M., Wang, M., Rabusa, C., Proudman, S., Nikpour, M., & Stevens, W. (2015). Health-Related Quality of Life in Early Systemic Sclerosis. ARTHRITIS & RHEUMATOLOGY, 67, 2 pages. 2015 Ferdowsi, N., Huq, M., Burchell, J., Mancuso, S., Tay, T., Stevens, W., . . . Nikpour, M. (2015). Development of a Disease Damage Index in Systemic Sclerosis Using Consensus and Data Driven Methods. ARTHRITIS & RHEUMATOLOGY, 67, 2 pages. 2015 Wodkowski, M., Hudson, M., Proudman, S., Walker, J., Stevens, W., Nikpour, M., . . . Fritzler, M. (2015). Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. Autoimmunity, 48(8), 542-551.
Scopus10 WoS10 Europe PMC52015 Moore, O., Proudman, S., Goh, N., Corte, T., Rouse, H., Hennessy, O., . . . Nikpour, M. (2015). Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease. Clinical and Experimental Rheumatology, 33(4 (Suppl. 91)), 111-116.
Scopus38 WoS382015 Wodkowski, M., Hudson, M., Proudman, S., Walker, J., Stevens, W., Nikpour, M., . . . Salazar, G. (2015). Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: Evidence of an association with interstitial lung disease and worse survival. Clinical and Experimental Rheumatology, 33(4), 131-135.
Scopus20 WoS21 Europe PMC122015 Bartold, P., & Proudman, S. (2015). Is there evidence indicating a link between periodontitis and rheumatoid arthritis?. International Journal of Clinical Rheumatology, 10(4), 215-218.
2015 Quinlivan, A., Thakkar, V., Stevens, W., Morrisroe, K., Prior, D., Rabusa, C., . . . Nikpour, M. (2015). Cost savings with a new screening algorithm for pulmonary arterial hypertension in systemic sclerosis. Internal Medicine Journal, 45(11), 1134-1140.
Scopus16 WoS13 Europe PMC72015 Hopkins, A., Wiese, M., Proudman, S., O'Doherty, C., Foster, D., & Upton, R. (2015). Semiphysiologically based pharmacokinetic model of leflunomide disposition in rheumatoid arthritis patients. CPT: Pharmacometrics and Systems Pharmacology, 4(6), 362-371.
Scopus9 Europe PMC62015 Patterson, K., Roberts-Thomson, P., Lester, S., Tan, J., Hakendorf, P., Rischmueller, M., . . . Walker, J. (2015). Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (Scleroderma) cohort using principal components analysis. Arthritis and Rheumatology, 67(12), 3234-3244.
Scopus49 WoS51 Europe PMC222015 Proudman, S., Cleland, L., Metcalf, R., Sullivan, T., Spargo, L., & James, M. (2015). Plasma n-3 fatty acids and clinical outcomes in recent-onset rheumatoid arthritis. The British Journal of Nutrition, 114(06), 885-890.
Scopus14 WoS15 Europe PMC132015 Thakkar, V., Nikpour, M., Stevens, W., & Proudman, S. (2015). Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension. Internal Medicine Journal, 45(3), 248-254.
Scopus7 WoS6 Europe PMC32015 Bright, R., Proudman, S., Rosenstein, E., & Bartold, P. (2015). Is there a link between carbamylation and citrullination in periodontal disease and rheumatoid arthritis?. Medical Hypotheses, 84(6), 570-576.
Scopus15 WoS15 Europe PMC102015 Moghaddami, M., James, M., Proudman, S., & Cleland, L. (2015). Synovial fluid and plasma n3 long chain polyunsaturated fatty acids in patients with inflammatory arthritis. Prostaglandins Leukotrienes and Essential Fatty Acids, 97, 7-12.
Scopus7 WoS7 Europe PMC22015 Wabe, N., Sorich, M., Wechalekar, M., Cleland, L., McWilliams, L., Lee, A., . . . Wiese, M. (2015). Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years. Arthritis Research and Therapy, 17(1), 48-1-48-14.
Scopus16 WoS18 Europe PMC102015 Mohamed, H., Sorich, M., Kowalski, S., McKinnon, R., Proudman, S., Cleland, L., & Wiese, M. (2015). The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies - a systematic review. European Journal of Clinical Pharmacology, 71(4), 411-423.
Scopus9 WoS8 Europe PMC52015 Khanna, D., Mittoo, S., Aggarwal, R., Proudman, S., Dalbeth, N., Matteson, E., . . . Strand, V. (2015). Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - report from OMERACT CTD-ILD Working Group. The Journal of rheumatology, 42(11), 2168-2171.
Scopus61 WoS65 Europe PMC352015 Morrisroe, K., Nikpour, M., & Proudman, S. (2015). Musculoskeletal manifestations of systemic sclerosis. Rheumatic Disease Clinics of North America, 41(3), 507-518.
Scopus21 WoS18 Europe PMC72015 Wojciechowski, J., Wiese, M., Proudman, S., Foster, D., & Upton, R. (2015). A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine. British journal of clinical pharmacology, 79(5), 777-788.
Scopus5 WoS4 Europe PMC42015 Hao, Y., Thakkar, V., Stevens, W., Morrisroe, K., Prior, D., Rabusa, C., . . . Nikpour, M. (2015). A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Research and Therapy, 17(1), 23.
Scopus49 WoS51 Europe PMC302015 Proudman, S., James, M., Spargo, L., Metcalf, R., Sullivan, T., Rischmueller, M., . . . Cleland, L. (2015). Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. Annals of the Rheumatic Diseases, 74(1), 89-95.
Scopus87 WoS80 Europe PMC542015 McComish, J., Mundy, J., Sullivan, T., Proudman, S., & Hissaria, P. (2015). Changes in peripheral blood B cell subsets at diagnosis and after treatment with disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: correlation with clinical and laboratory parameters. International Journal of Rheumatic Diseases, 18(4), 421-432.
Scopus9 WoS9 Europe PMC52014 Wiese, M., Alotaibi, N., O'Doherty, C., Sorich, M., Suppiah, V., Cleland, L., & Proudman, S. (2014). Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis. Pharmacogenomics Journal, 14(4), 350-355.
Scopus17 WoS15 Europe PMC112014 Saketkoo, L., Mittoo, S., Huscher, D., Khanna, D., Dellaripa, P., Distler, O., . . . Seibold, J. (2014). Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax, 69(5), 428-436.
Scopus65 WoS67 Europe PMC402014 Cleland, L., Proudman, S., & James, M. (2014). RE: plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. Journal of the National Cancer Institute, 106(4), dju022-1.
Scopus2 WoS2 Europe PMC22014 Kaur, S., Bright, R., Proudman, S., & Bartold, P. (2014). Does periodontal treatment influence clinical and biochemical measures for rheumatoid arthritis? A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 44(2), 113-122.
Scopus64 WoS53 Europe PMC372014 Hopkins, A., O'Doherty, C., Foster, D., Suppiah, V., Upton, R., Spargo, L., . . . Wiese, M. (2014). The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity. Journal of Clinical Pharmacy and Therapeutics, 39(5), 555-560.
Scopus6 WoS5 Europe PMC42014 Hopkins, A. M., O'Doherty, C. E., Foster, D. J. R., Upton, R. N., Proudman, S. M., & Wiese, M. D. (2014). Individualization of leflunomide dosing in rheumatoid arthritis patients. Personalized Medicine, 11(4), 449-461.
Scopus6 WoS62014 Black, R., Spargo, L., Schultz, C., Chatterton, B., Cleland, L., Lester, S., . . . Proudman, S. (2014). Decline in hand bone mineral density indicates increased risk of erosive change in early rheumatoid arthritis. Arthritis Care & Research, 66(4), 515-522.
Scopus10 WoS10 Europe PMC62014 Vacca, A., Meune, C., Gordon, J., Chung, L., Proudman, S., Assassi, S., . . . Allanore, Y. (2014). Cardiac arrhythmias and conduction defects in systemic sclerosis. Rheumatology, 53(7), 1172-1177.
Scopus43 WoS42 Europe PMC232014 Morrisroe, K., Stevens, W., Nandurkar, H., Prior, D., Thakkar, V., Roddy, J., . . . Nikpour, M. (2014). The association of antiphospholipid antibodies with cardiopulmonary manifestations of systemic sclerosis. Clinical and Experimental Rheumatology, 32(6 Suppl. 86), S133-S137.
Scopus21 WoS15 Europe PMC62014 Hudson, M., Baron, M., Tatibouet, S., Furst, D., Khanna, D., Hummers, L., . . . Westhovens, R. (2014). Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the international scleroderma renal crisis survey. Seminars in Arthritis and Rheumatism, 43(5), 666-672.
Scopus68 Europe PMC332014 Lake, F., & Proudman, S. (2014). Rheumatoid arthritis and lung disease: from mechanisms to a practical approach. Seminars in Respiratory and Critical Care Medicine, 35(2), 222-238.
Scopus39 WoS36 Europe PMC142014 Osthoff, M., Ngian, G., Dean, M., Nikpour, M., Stevens, W., Proudman, S., . . . Sahhar, J. (2014). Potential role of the lectin pathway of complement in the pathogenesis and disease manifestations of systemic sclerosis: a case-control and cohort study. Arthritis Research and Therapy, 16(1), 480-1-480-11.
Scopus10 WoS10 Europe PMC72014 Zochling, J., Newell, F., Charlesworth, J., Leo, P., Stankovich, J., Cortes, A., . . . Brown, M. (2014). An immunochip-based interrogation of scleroderma susceptibility variants identifies a novel association at DNASE1L3. Arthritis Research & Therapy, 16(5), 438-1-438-7.
Scopus30 WoS29 Europe PMC202014 Wiese, M. D., Hopkins, A., Spargo, L., McWilliams, L., O'Doherty, C., Cleland, L. G., & Proudman, S. (2014). Patient, Genetic and Disease Factors Influence the Response to the Disease Modifying Anti-Rheumatic Drug Leflunomide. ARTHRITIS & RHEUMATOLOGY, 66, S1102. 2013 Thakkar, V., Stevens, W., Prior, D., Youssef, P., Liew, D., Gabbay, E., . . . Nikpour, M. (2013). The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. Arthritis Research & Therapy, 15(6), R193-1-R193-11.
Scopus32 WoS30 Europe PMC202013 Nikpour, M., Stevens, W., Proudman, S., Buchbinder, R., Prior, D., Zochling, J., . . . Nandurkar, H. (2013). Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated?. Internal Medicine Journal, 43(5), 599-603.
Scopus9 WoS9 Europe PMC42013 Moore, O., Goh, N., Corte, T., Rouse, H., Hennessy, O., Thakkar, V., . . . Nikpour, M. (2013). Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology, 52(1), 155-160.
Scopus106 WoS98 Europe PMC642012 Ngian, G., Sahhar, J., Proudman, S., Stevens, W., Wicks, I., & Van Doornum, S. (2012). Prevalence of coronary heart disease and cardiovascular risk factors in a national cross-sectional cohort study of systemic sclerosis. ARD online, 71(12), 1980-1983.
Scopus63 WoS57 Europe PMC292012 O'Doherty, C., Schnabl, M., Spargo, L., Cleland, L., James, M., Proudman, S., & Wiese, M. (2012). Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis. Pharmagenomics, 13(12), 1427-1434.
Scopus18 WoS17 Europe PMC142012 Thakkar, V., Stevens, W., Prior, D., Moore, O., Byron, J., Liew, D., . . . Nikpour, M. (2012). N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. Arthritis Research & Therapy, 14(3), 1-10.
Scopus64 WoS59 Europe PMC352012 Graf, S., Lester, S., Nossent, J., Hill, C., Proudman, S., Lee, A., & Rischmueller, M. (2012). Low copy number of the FCGR3B gene and rheumatoid arthritis: a case-control study and meta-analysis. Arthritis Research & Therapy, 14(1), 1-7.
Scopus26 WoS27 Europe PMC192012 Wechalekar, M., Lester, S., Proudman, S., Cleland, L., Whittle, S., Rischmueller, M., & Hill, C. (2012). Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement. Arthritis and Rheumatism, 64(5), 1316-1322.
Scopus36 WoS33 Europe PMC232012 Ngian, G., Stevens, W., Prior, D., Gabbay, E., Roddy, J., Tran, A., . . . Nikpour, M. (2012). Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Research & Therapy, 14(R213), 1-9.
Scopus53 WoS55 Europe PMC382012 Marchant, C., Smith, M., Proudman, S., Haynes, D., & Bartold, P. (2012). Effect of Porphyromonas gingivalis on citrullination of proteins by macrophages in vitro. Journal of Periodontology, Online(9), 1-15.
Scopus10 WoS12 Europe PMC72012 Wiese, M., Schnabl, M., O'Doherty, C., Spargo, L., Sorich, M., Cleland, L., & Proudman, S. (2012). Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. Arthritis Research & Therapy, 14(4), 1-9.
Scopus32 WoS31 Europe PMC242012 Dalton, B., McNeil, K., Keogh, A., Williams, T., Proudman, S., Gabbay, E., . . . Boland, J. (2012). Design and delivery of an e-learning curriculum for physicians involved in the management of pulmonary hypertension. International Journal of Clinical Practice, 66(11), 1117-1124.
Scopus12012 Chen, J., Limaye, V., Jain, R., Lu, T., Proudman, S., & Raymond, G. (2012). Pulsed intravenous cyclophosphamide for SLE retinal vasculitis. Retinal Cases and Brief Reports, 6(1), 111-115.
2011 Black, R., Limaye, V., Proudman, S., Spargo, L., & Cleland, L. (2011). THE UTILITY OF THE VITAL ACTIVITIES AND LIFESTYLE INDEX (VALI) IN THE ASSESSMENT OF FIBROMYALGIA PATIENTS. INTERNAL MEDICINE JOURNAL, 41, 28-29. 2011 Cohen, S., Proudman, S., Kivitz, A., Burch, F., Donohue, J., Burstein, D., . . . Zack, D. (2011). A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Research and Therapy, 13(4), R125-1-R125-12.
Scopus106 WoS88 Europe PMC752011 Nikpour, M., Hissaria, P., Byron, J., Sahhar, J., Micallef, M., Paspaliaris, W., . . . Stevens, W. (2011). Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Research & Therapy, 13(6), 1-13.
Scopus97 WoS85 Europe PMC612011 Gregory, M., Lester, S., Cook-Johnson, R., Gibson, R., Proudman, S., Cleland, L., & James, M. (2011). Fatty acid desaturase 2 promoter mutation is not responsible for Δ6-desaturase deficiency. European Journal of Human Genetics, 19(11), 1202-1204.
Scopus6 WoS4 Europe PMC22011 Rakhila, H., Rozek, T., Hopkins, A., Proudman, S., Cleland, L., James, M., & Wiese, M. (2011). Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 55(2), 325-331.
Scopus26 WoS27 Europe PMC122011 Keogh, A., Strange, G., McNeil, K., Williams, T., Gabbay, E., Proudman, S., . . . Dalton, B. (2011). The Bosentan Patient Registry: long-term survival in pulmonary arterial hypertension. Internal Medicine Journal, 41(3), 227-234.
Scopus24 WoS23 Europe PMC192011 Ngian, G., Nikpour, M., Byron, J., Tran, A., Roddy, J., Minson, R., . . . Proudman, S. (2011). SURVIVAL IN AUSTRALIAN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION. INTERNAL MEDICINE JOURNAL, 41, 12.
WoS22011 Nikpour, M., Proudman, S., Byron, J., Zochling, J., Roddy, J., Sahhar, J., . . . Stevens, W. (2011). MORTALITY AND CAUSES OF DEATH IN AN AUSTRALIAN SYSTEMIC SCLEROSIS COHORT. INTERNAL MEDICINE JOURNAL, 41, 12. 2011 Bejarano, V., Conaghan, P. G., & Proudman, S. M. (2011). Long-term efficacy and toxicity of ciclosporin A in combination with methotrexate in poor prognosis rheumatoid arthritis (Annals of the Rheumatic Diseases (2009) 68, (761-763)). Annals of the Rheumatic Diseases, 70(8), 1519.
2010 Nikpour, M., Micallef, M., Byron, J., Hissaria, P., Paspaliaris, W., Sahhar, J., . . . Stevens, W. (2010). PREVALENCE AND CORRELATES OF ANTIBODIES TO RNA POLYMERASE Ill IN SYSTEMIC SCLEROSIS. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 28(2), S82. 2010 Stevens, W., Byron, J., Nash, P., Zochling, J., Gabbay, E., Chan, M., . . . Proudman, S. (2010). PULMONARY ARTERIAL HYPERTENSION IN AN AUSTRALIAN SYSTEMIC SCLEROSIS COHORT. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 28(2), S76-S77. 2010 Proudman, S. (2010). Why screen patients with scleroderma for lung complications?. Medicine Today, 11(2), 63-68. 2010 Nikpour, M., Byron, J., Zochling, J., Chan, M., Nash, P., Sahhar, J., . . . Stevens, W. (2010). DESCRIBING ORGAN DAMAGE IN SYSTEMIC SCLEROSIS. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 28(2), S113-S114. 2010 Caughey, G., James, M., Proudman, S., & Cleland, L. (2010). Fish oil supplementation increases the cyclooxygenase inhibitory activity of paracetamol in rheumatoid arthritis patients. Complementary Therapies in Medicine, 18(3-4), 171-174.
Scopus25 WoS23 Europe PMC112010 Nikpour, M., Stevens, W., Herrick, A., & Proudman, S. (2010). Epidemiology of systemic sclerosis. Best Practice & Research Clinical Rheumatology, 24(6), 857-869.
Scopus63 WoS54 Europe PMC412010 Nikpour, M., Proudman, S. M., Goh, N. S., & Moutsopoulos, H. M. (2010). Interstitial lung disease in Sjogren's syndrome. Current Rheumatology Reviews, 6(2), 127-137.
2010 Mangat, P., Conron, M., Gabbay, E., & Proudman, S. (2010). Scleroderma lung disease, variation in screening, diagnosis and treatment practices between rheumatologists and respiratory physicians. Internal Medicine Journal, 40(7), 494-502.
Scopus7 WoS6 Europe PMC42009 Lester, S., Proudman, S., Lee, A., Hall, C., McWilliams, L., James, M., & Cleland, L. (2009). Treatment-induced stable, moderate reduction in blood cell counts correlate to disease control in early rheumatoid arthritis. Internal Medicine Journal, 39(5), 296-303.
Scopus9 WoS8 Europe PMC52009 Cleland, L., James, M., & Proudman, S. (2009). Dietary fats and inflammation: The medicinal use of fish oil. Nutrition & Dietetics, 66(1), 4-6.
Scopus1 WoS12009 Bejarano, V., Conaghan, P. G., Proudman, S. M., Buch, M. H., Brown, A. K., & Emery, P. (2009). Long-term efficacy and toxicity of ciclosporin A in combination with methotrexate in poor prognosis rheumatoid arthritis. Annals of the Rheumatic Diseases, 68(5), 761-763.
Scopus4 Europe PMC32008 Proudman, S., Cleland, L., & James, M. (2008). Dietary omega-3 fats for treatment of inflammatory joint disease: Efficacy and utility. Rheumatic Disease Clinics of North America, 34(2), 469-479.
Scopus43 WoS42 Europe PMC252008 Cai, F., Lester, S., Lu, T., Keen, H., Boundy, K., Proudman, S., . . . Rischmueller, M. (2008). Mild autonomic dysfunction in primary Sjogren's syndrome: a controlled study. Arthritis Research & Therapy, 10(2), R31-1-R31-10.
Scopus30 WoS27 Europe PMC162008 James, H., Gillis, D., Hissaria, P., Lester, S., Somogyi, A., Cleland, L., & Proudman, S. (2008). Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. Journal of Rheumatology, 35(4), 562-571.
Scopus48 WoS48 Europe PMC352008 Philpott, H., Hissaria, P., Warren, L., Singhal, N., Brown, M., Proudman, S., . . . Gillis, D. (2008). Eosinophilic fasciitis as a paraneoplastic phenomenon associated with metastatic colorectal carcinoma. Australasian Journal of Dermatology, 49(1), 27-29.
Scopus15 WoS11 Europe PMC32007 Proudman, S., Keen, H., Stamp, L., Lee, A., Goldblatt, F., Ayres, O., . . . Cleland, L. (2007). Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Seminars in Arthritis and Rheumatism, 37(2), 99-111.
Scopus53 WoS55 Europe PMC412007 Haugeberg, G., Green, M., Conaghan, P., Quinn, M., Wakefield, R., Proudman, S., . . . Emery, P. (2007). Hand bone densitometry: A more sensitive standard for the assessment of early bone damage in rheumatoid arthritis. Annals of the Rheumatic Diseases, 66(11), 1513-1517.
Scopus35 WoS30 Europe PMC222007 Cox, S., McWilliams, L., Massy-Westropp, N., Meads, D., McKenna, S., & Proudman, S. (2007). Adaptation of the RAQoL for use in Australia. Rheumatology International, 27(7), 661-666.
Scopus12 WoS14 Europe PMC72007 Marzo-Ortega, H., Green, M., Keenan, A., Wakefield, R., Proudman, S., & Emery, P. (2007). A randomized controlled trial of early intervention with intraarticular corticosteroids followed by sulfasalazine versus conservative treatment in early oligoarthritis. Arthritis Care and Research, 57(1), 154-160.
Scopus23 WoS22 Europe PMC192007 Proudman, S., Cleland, L., & James, M. (2007). Omega-3 fatty acids for early rheumatoid arthritis. Medicine Today, 8(12), 57-59. 2007 Proudman, S., Stevens, W., Sahhar, J., & Celermajer, D. (2007). Pulmonary arterial hypertension in systemic sclerosis: The need for early detection and treatment. Internal Medicine Journal, 37(7), 485-494.
Scopus92 WoS92 Europe PMC642006 Cleland, L. G., James, M. J., & Proudman, S. M. (2006). Erratum: Fish oil: What the prescriber needs to know (Arthritis Research and Therapy). Arthritis Research and Therapy, 8(4), 1 page.
Scopus1 WoS12006 Cleland, L., Caughey, G., James, M., & Proudman, S. (2006). Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis. Journal of Rheumatology, 33(10), 1973-1979.
Scopus82 WoS73 Europe PMC312006 Roberts, L., Cleland, L., Thomas, R., & Proudman, S. (2006). Early combination disease modifying antirheumatic drug treatment for rheumatoid arthritis. Medical Journal of Australia, 184(3), 122-125.
Scopus17 WoS11 Europe PMC72006 Cleland, L., James, M., & Proudman, S. (2006). Fish oil: what the prescriber needs to know. Arthritis Research & Therapy, 8(1), WWW1-WWW9.
Scopus87 WoS71 Europe PMC322006 Haugeberg, G., Green, M. J., Quinn, M. A., Marzo-Ortega, H., Proudman, S., Karin, Z., . . . Emery, P. (2006). Hand bone loss in early undifferentiated arthritis: Evaluating bone mineral density loss before the development of rheumatoid arthritis. Annals of the Rheumatic Diseases, 65(6), 736-740.
Scopus64 Europe PMC472005 Cleland, L., James, M., Keen, H., Danda, D., Caughey, G., & Proudman, S. (2005). Fish oil - an example of an anti-inflammatory food. Asia Pacific Journal of Clinical Nutrition, 14(SUPPL.), 66-71.
Scopus72005 Cox, S., Walker, J., Coleman, M., Rischmueller, M., Proudman, S., Smith, M., . . . Roberts-Thomson, P. (2005). Isolated pulmonary hypertension in scleroderma. Internal Medicine Journal, 35(1), 28-33.
Scopus57 WoS54 Europe PMC312005 Broadfoot, A., Gillis, D., & Proudman, S. (2005). Lack of association of antineutrophil cytoplasmic antibodies with joint failure as indicated by joint surgery in rheumatoid arthritis. APLAR Journal of Rheumatology, 8(1), 54-59.
2004 Wakefield, R., Green, M., Marzo-Ortega, H., Conaghan, P., Gibbon, W., McGonagle, D., . . . Emery, P. (2004). Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. Annals of the Rheumatic Diseases, 63(4), 382-385.
Scopus296 WoS280 Europe PMC1712003 Cleland, L., James, M., & Proudman, S. (2003). The role of fish oils in the treatment of rheumatoid arthritis. Drugs, 63(9), 845-853.
Scopus126 WoS110 Europe PMC592003 Cleland, L., Proudman, S., Hall, C., Stamp, L., McWilliams, L., Wylie, N., . . . James, M. (2003). A Biomarker of n-3 compliance in patients taking fish oil for rheumatoid arthritis. Lipids, 38(4), 419-424.
Scopus18 WoS20 Europe PMC142003 James, M., Proudman, S., & Cleland, L. (2003). Dietary n-3 fats as adjunctive therapy in a prototypic inflammatory disease: issues and obstacles for use in rheumatoid arthritis. Prostaglandins Leukotrienes and Essential Fatty Acids, 68(6), 399-405.
Scopus47 WoS42 Europe PMC232003 Quinn, M., Green, M., Marzo-Ortega, H., Proudman, S., Karim, Z., Wakefield, R., . . . Emery, P. (2003). Prognostic Factors in a Large Cohort of Patients With Early Undifferentiated Inflammatory Arthritis After Application of a Structured Management Protocol. Arthritis and Rheumatism, 48(11), 3039-3045.
Scopus93 Europe PMC482003 Conaghan, P. G., O'Connor, P., McGonagle, D., Astin, P., Wakefield, R. J., Gibbon, W. W., . . . Emery, P. (2003). Elucidation of the relationship between synovitis and bone damage: A randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis and Rheumatism, 48(1), 64-71.
Scopus305 Europe PMC1932001 Green, M., Marzo-Ortega, H., Wakefield, R., Astin, P., Proudman, S., Conaghan, P., . . . Emery, P. (2001). Predictors of outcome in patients with oligoarthritis - Results of a protocol of intraarticular corticosteroids to all clinically active joints. Arthritis and Rheumatism, 44(5), 1177-1183.
Scopus40 WoS37 Europe PMC222001 Cleland, L., Fusco, M., Proudman, S., Wing, S., Spargo, L., & Mayrhofer, G. (2001). Recruitment of mononuclear leucocytes to osteoarthritic human synovial xenografts in the ears of SCID mice. Immunology and Cell Biology, 79(4), 309-319.
2000 Cleland, L., Proudman, S., James, M., & Penglis, P. (2000). The changing treatment of arthritis. Australian Prescriber, 23(2), 26-27.
Scopus12000 Proudman, S. M., Conaghan, P. G., Richardson, C., Griffiths, B., Green, M. J., Mcgonagle, D., . . . Emery, P. (2000). Treatment of poor-prognosis early rheumatoid arthritis: A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis and Rheumatism, 43(8), 1809-1819.
Scopus134 Europe PMC611999 Proudman, S., Cleland, L., & Mayrhofer, G. (1999). Effects of TNF-a, IL-1b and activated peripheral blood mononuclear cells on the expression of adhesion molecules and recruitment of leukocytes in rheumatoid synovial xenografts in SCID mice.. Journal of Rheumatology, 26(9), 1877-1889.
Scopus24 WoS23 Europe PMC171999 Proudman, S., Cleland, L., & Mayrhofer, G. (1999). Effects of Tumor Necrosis Factor-a, Interleukin 1B, and Activated Peripheral Blood Mononuclear Cells on the Expression of Adhesion Molecules and Recruitment of Leukocytes in Rheumatoid Synovial Xenografts in SCID Mice. Journal of Rheumatology, 26(9, September 1999), 1877-1889. 1999 Proudman, S., Cleland, L., Fusco, M., & Mayrhofer, G. (1999). Accessible xenografts of human synovium in the subcutaneous tissues of the ears of SCID mice. Immunology and Cell Biology, 77(2, April 1999), 109-120.
Scopus6 WoS7 Europe PMC41999 Green, M., Marzo-Ortega, H., McGonagle, D., Wakefield, R., Proudman, S., Conaghan, P., . . . Emery, P. (1999). Persistence of mild, early inflammatory arthritis: The importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis and Rheumatism, 42(10), 2184-2188.
Scopus163 WoS136 Europe PMC751994 Hawkes, J., Cleland, L., Proudman, S., & James, M. (1994). The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis. Journal of Rheumatology, 21(1), 55-58.
Scopus20 WoS21 Europe PMC151994 Cleland, L., James, M., Proudman, S., Neumann, M., & Gibson, R. (1994). Inhibition of human neutrophil leukotriene B<inf>4</inf> synthesis in essential fatty acid deficiency: Role of leukotriene a hydrolase. Lipids, 29(3), 151-155.
Scopus17 WoS16 Europe PMC91994 James, M., Cleland, L., Gaffney, R., Proudman, S., & Chatterton, B. (1994). Effect of exercise on <sup>99m</sup>Tc-DTPA clearance from knees with effusions. Journal of Rheumatology, 21(3), 501-504.
Scopus22 WoS21 Europe PMC181992 Proudman, S., & Cleland, L. (1992). Auranofin‐induced vasomotor reaction. Arthritis & Rheumatism, 35(12), 1452-1454.
Scopus4 WoS5 Europe PMC21992 CLELAND, L., JAMES, M., PROUDMAN, S., NEUMANN, M., & GIBSON, R. (1992). INHIBITION OF HUMAN NEUTROPHIL LEUKOTRIENE-B4 PRODUCTION BY N-9 EICOSTRIENOIC ACID. ARTHRITIS AND RHEUMATISM, 35(9), S36. -
Book Chapters
-
Conference Papers
Year Citation 2020 Small, A., Murray-Brown, W., Guo, Y., Weedon, H., Proudman, S., Smith, M., . . . Wechalekar, M. (2020). CHARACTERISATION OF PROGRAMMED CELL DEATH PROTEIN 1 EXPRESSING PERIPHERAL T HELPER CELLS IN THE EARLY RHEUMATOID ARTHRITIS SYNOVIUM. In INTERNAL MEDICINE JOURNAL Vol. 50 (pp. 42-43). WILEY. 2019 Valenzuela, A., Chung, M., Rodriguez-Reyna, T. S., Proudman, S., Baron, M., Castelino, F., . . . Chung, L. (2019). Change in Calcinosis over 1 Year Using the SCTC Radiologic Scoring System for Calcinosis of the Hands in Patients with Systemic Sclerosis. In ARTHRITIS & RHEUMATOLOGY Vol. 71 (pp. 3 pages). WILEY. 2018 Boulos, D., Metcalf, R., Proudman, S., & Wicks, I. (2018). The Neutrophil-Lymphocyte Ratio in Newly Diagnosed Rheumatoid Arthritis and Its Ability to Predict Treatment Failure. In ARTHRITIS & RHEUMATOLOGY Vol. 70 (pp. 1 page). WILEY. 2018 Day, J., Otto, S., Cash, K., Eldi, P., Hissaria, P., Proudman, S., . . . Limaye, V. (2018). Aberrant Sarcoplasmic Expression of the Alarmin 'High Mobility Group Box Protein 1 '' (HMGB1) in Patients with Idiopathic Inflammatory Myopathy. In ARTHRITIS & RHEUMATOLOGY Vol. 70 (pp. 2 pages). WILEY. 2018 Reid, A., Wiese, M. D., Metcalf, R., Wechalekar, M. D., Lee, A., Hill, C., . . . Proudman, S. (2018). Utility of Serial ACPA Measurements in Rheumatoid Arthritis: Results of a Prospective Cohort Study. In ARTHRITIS & RHEUMATOLOGY Vol. 70 (pp. 2 pages). WILEY. 2016 Guo, Y., Walsh, A., Fearon, U., Smith, M. D., Wechalekar, M. D., Yin, X., . . . Nagpal, S. (2016). Gene Enrichment Analysis Identifies Active CD40-CD40L Signaling in Early and Established Rheumatoid Arthritis. In ARTHRITIS & RHEUMATOLOGY Vol. 68 (pp. 1 page). WILEY. 2016 Morrisroe, K., Huq, M., Stevens, W., Sahhar, J., Proudman, S., & Nikpour, M. (2016). Work Productivity in Systemic Sclerosis and Association with Health Related Quality of Life. In ARTHRITIS & RHEUMATOLOGY Vol. 68 (pp. 3 pages). WILEY.
WoS22016 Wechalekar, M. D., Lester, S., Nagpal, S., Peters, J., Dash, A., Hissaria, P., . . . Proudman, S. M. (2016). Seropositivity Predicts Bone Biomarker Change in an Inception Cohort of Rheumatoid Arthritis Patients Treated-to-Target with Combination Conventional DMARD Therapy. In ARTHRITIS & RHEUMATOLOGY Vol. 68 (pp. 2 pages). WILEY. 2016 Valenzuela, A., Gordon, J. K., Sofia Rodriguez-Reyna, T., Proudman, S., Baron, M., Hinchcliff, M., . . . Chung, L. (2016). Comprehensive Characterization of Calcinosis in a Multicenter International Cohort of Patients with Systemic Sclerosis. In ARTHRITIS & RHEUMATOLOGY Vol. 68 (pp. 2 pages). WILEY. 2016 Khanna, D., Proudman, S., Frech, T. M., Nihtyanova, S., Domsic, R. T., Berrocal, V. J., . . . Denton, C. P. (2016). Performance of Modified Rodnan Skin Score in Early Diffuse Cutaneous Scleroderma-Analysis from 4 International Cohorts. In ARTHRITIS & RHEUMATOLOGY Vol. 68 (pp. 3 pages). WILEY. 2011 Patterson, K., Sakko, A., Ricciardelli, C., Proudman, S., & Hissaria, P. (2011). EVALUATION OF ANGIOGENIC AND FIBROGENIC CYTOKINES AS BIOMARKERS IN SUBGROUPS OF SYSTEMIC SCLEROSIS. In INTERNAL MEDICINE JOURNAL Vol. 41 (pp. 9-10). WILEY-BLACKWELL. 2011 Hill, C. L., Jones, G., March, L., Battersby, R., Hynes, K., Fedorova, T., . . . Cleland, L. G. (2011). Fish Oil in Knee Osteoarthritis: A Two Year Randomized, Double-Blind Clinical Trial Comparing High Dose with Low Dose. In ARTHRITIS AND RHEUMATISM Vol. 63 (pp. S426). Chicago, IL: WILEY-BLACKWELL. 2011 Ngian, G. -S., Stevens, W., Byron, J., Ai, T., Roddy, J. E., Minson, R., . . . Nikpour, M. (2011). Survival and Predictors of Mortality In Australian Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. In ARTHRITIS AND RHEUMATISM Vol. 63 (pp. S332). Chicago, IL: WILEY-BLACKWELL.
WoS12010 James, M., Proudman, S., & Cleland, L. (2010). Fish oil and rheumatoid arthritis: past, present and future. In Proceedings of the 3rd International Immunonutrition Workshop Vol. 69 (pp. 316-323). UK: Cambridge University Press.
Scopus57 WoS52 Europe PMC322007 Cleland, L., Caughey, G., Proudman, S., James, M., & Lee, A. (2007). Fish oil treatment and cardiovascular risk in early rheumatoid arthritis. In ANNALS OF THE RHEUMATIC DISEASES Vol. 66 (pp. 347). Barcelona, SPAIN: B M J PUBLISHING GROUP.
WoS12007 Lee, X., Proudman, S., Phillips, M., Slavotinek, J., & Cleland, L. (2007). High resolution musculoskeletal sonography in early arthritis: Can we predict outcome?. In ANNALS OF THE RHEUMATIC DISEASES Vol. 66 (pp. 94). Barcelona, SPAIN: B M J PUBLISHING GROUP. 2006 James, H., Gillis, D., Hissaria, P., Lester, S., Somogyi, A., Cleland, L., & Proudman, S. (2006). Polymorphisms in the folate pathway predict response to methotrexate in early RA.. In ARTHRITIS AND RHEUMATISM Vol. 54 (pp. S129). Washington, DC: WILEY-LISS. 2005 Marzo-Ortega, H., Green, M., Keenan, A., Wakefield, R., Proudman, S., & Emery, P. (2005). A randomised trial of intra-articular corticosteroids versus conservative treatment in early oligoarthritis over 12 months. In RHEUMATOLOGY Vol. 44 (pp. I90). Birmingham, ENGLAND: OXFORD UNIV PRESS. 2004 Marzo-Ortega, H., Green, M., Keenan, A., Wakefield, R., Proudman, S., & Emery, P. (2004). A randomised trial of intra-articular corticosteroids versus conservative treatment in early oligoarthritis over 12 months. In ARTHRITIS AND RHEUMATISM Vol. 50 (pp. S130-S131). San Antonio, TX: WILEY-LISS.
WoS12004 Proudman, S. (2004). Tracleer (bosentan), a dual endothelin receptor antagonist (ERA), for the treatment of pulmonary arterial hypertension (PAH) related to connective tissue diseases: Effect on quality of life (QoL). In ARTHRITIS AND RHEUMATISM Vol. 50 (pp. S692). San Antonio, TX: WILEY-LISS. 1999 Emery, P., Marzo, H., & Proudman, S. (1999). Management of patients with newly diagnosed rheumatoid arthritis. In Rheumatology Vol. 38 (pp. 27-31). England.
Scopus27 Europe PMC71998 Proudman, S. (1998). Aggressive combination therapy provides clinical improvement for RA. In Geriatrics Vol. 53 (pp. 67-68). -
Conference Items
Grants and Funding
2009-2012 | Identification of microRNAs in Scleroderma. | Goodall Y, Goodall G, Proudman S, Hissaria P | NHMRC Project Grant ID 626945 | $138 500 p.a. |
2010-2013 | Unrestricted educational grant, Actelion Australia | Proudman S, Stevens W, Roddy J, Youssef P, Gabbay E. | Australian Scleroderma Interest Group | $450 000 |
2011 | Therapeutic drug monitoring of leflunomide | Wiese M, Proudman S, O’Doherty, James M, Cleland L | Arthritis Australia Barbara Cameron Memorial Grant | $15 000 |
2011 | A novel screening biomarker in screening for PAH in SSc | Stevens W, Proudman S, Nikpour M. | Arthritis Australia project grant | $20 000 |
2011 | SSc serum microenvironment dysregulates endothelial progenitor cell migration and tubulogenic ability and contributes to vasculopathy | Hissaria P, Bonder C, Proudman S, Patterson K. | Arthritis Australia grant-in-aid | $20 000 |
2011-2014 | How are periodontal disease and rheumatoid arthritis inter-related? | Bartold M, Smith M, Haynes D, Proudman SM | App. No. 023747 NHMRC | $544,261.00 |
2013 | Therapeutic drug monitoring in intensive therapy for rheumatoid arthritis using methotrexate loading | Proudman SM, Wiese M | Royal Adelaide Hospital Research Foundation | $35 000 |
2014 | Identification of factors that influence efficacy and toxicity with leflunomide in the treatment of rheumatoid arthritis | Wiese M, Proudman SM, Shanahan M | Arthritis Australia Grant in Aid | $14, 000 |
2014-2016 | A Clinical Trial of Anticoagulation in Scleroderma Heart-Lung Disease | Nikpour M, Buchbinder R, Prior D, Nandurkar H, Williams T, Gabbay E, Proudman S, Nash P, Zochling J, Stevens W. | NHMRC APP1062638 | $ 1,139,571 |
2015 | The effect of biological agent treatment of rheumatoid arthritis on periodontal disease. | Proudman S, Bartold M | RAH Research Fund | $35 000 |
2015 | VCAM1 as a therapeutic target in scleroderma | Brown M, Kenna T, Proudman S, Stevens W, Nikpour M | Arthritis Australia PG422015 | $25 000 |
2016 | Intracellular Disease Modifying Antirheumatic Drug Concentrations in Patients with Rheumatoid Arthritis | Proudman S, Moghaddami M, Wiese M | Royal Adelaide Hospital Research Foundation | $49 118 |
Teaching
I contribute to undergraduate teaching for the University of Adelaide School of Medicine, with lectures in years 2 and 4 and clinical skills workshops in years 3 and 4. I am the coordinator of the Rheumatology component of the 4th Year Medical Student musculoskeletal teaching programme. I have been involved in year 4, 5 and 6 clinical examinations and setting and marking exam questions.
Postgraduate teaching includes tutorials, short case rounds, long cases and trial examinations for basic physician trainees and supervision of advanced trainees in rheumatology (clinical and research). I have been the advanced training supervisor for more than 15 advanced trainees, and supervised many of these in research projects which have resulted in presentations and awards at national or international meetings and publications. I have supervised two vacation students, one Honours student and three PhD students.
I have examined one Master of Philosophy Thesis (The RAGE glycine 82 serine polymorphism and cardiovascular disease in rheumatoid arthritis, L Carroll, The University of Queensland Student Number 33160957) and one PhD, Monash University 2012.
I have examined for the Australian Medical Council and I am on the National Examination Panel for the Royal Australasian College of Physicians Membership exams.
-
Expand
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2020 Co-Supervisor Cardiopulmonary exercise testing for screening of pulmonary hypertension in a clinical population of Scleroderma patients. Doctor of Philosophy Doctorate Part Time Mrs Sarah Ann Madigan 2017 Co-Supervisor Optimising Therapy in Anca-Associated Vasculitis Doctor of Philosophy Doctorate Full Time Dr Joanna Tieu -
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2005 - 2010 Co-Supervisor Knowledge Engineering Complex Decision Support System in Managing Rheumatoid Arthritis Doctor of Philosophy Doctorate Full Time Ms Ning Pan 2002 - 2008 Co-Supervisor Applications of Real Time Musculoskeletal Ultrasonography in Rheumatology Practice Doctor of Philosophy Doctorate Full Time Dr Anita Lee -
Other Supervision Activities
Date Role Research Topic Location Program Supervision Type Student Load Student Name 2012 - 2015 External Supervisor OPTIMISING REMISSION AND TREATMENT OUTCOMES IN RHEUMATOID ARTHRITIS Flinders University Doctor of Philosophy Doctorate Part Time Mihir Wechalekar
-
Expand
-
Committee Memberships
Date Role Committee Institution Country 2016 - ongoing Member Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis working group — — 2015 - ongoing Member Systemic Sclerosis 4th World Congress Scientific Committee — — 2014 - ongoing Member Medical Director Arthritis Australia — — 2014 - ongoing Founder The Australian New Zealand Musculoskeletal Clinical Trials Group (ANZMusc) — — 2014 - ongoing Chair Australian Clinical Excellence Program Steering Committee — — 2013 - ongoing Member National Examiners Panel, Royal College of Physicians — — 2012 - ongoing Member Scleroderma Clinical Trials Consortium Damage Index working group — — 2011 - ongoing Member Pulmonary Hypertension Society ANZ Steering Committee — — 2011 - ongoing Member RAH Research Grants Committee — — 2011 - 2014 Member RAH Outpatient Clinical Leadership Group — — 2010 - ongoing Member Arthritis Australia Grant Review Committee — — 2010 - ongoing Member Australian Clinical Excellence Program Steering Committee — — 2009 - 2014 Member The Connective Tissue Disease associated Interstitial Lung Disease (CTD-ILD) working group of Outcome Measures in Rheumatology (OMERACT) — — 2006 - ongoing Member Pulmonary Interstitial Vascular, Orphan transplantation (PIVOT) committee Australian Lung Foundation — 2006 - ongoing Chair Australian Scleroderma Interest Group — — 1998 - ongoing Member Med IV Musculoskeletal Clinical Sciences Committee — — -
Memberships
Date Role Membership Country 2013 - ongoing Member American College of Rheumatology — 2009 - ongoing Member Scleroderma Clinical Trials Consortium — 2009 - ongoing Member South Australian Salaried Medical Officers Association — 1997 - ongoing Member Australian Rheumatology Association — -
Consulting/Advisories
Date Institution Department Organisation Type Country 2008 - 2014 ARA Arthritis Research Trust Scientific Advisory Board — — —
Connect With Me
External Profiles